Clinical Applicability of Ultrasound in Systemic Large Vessel Vasculitides

2019 ◽  
Vol 71 (11) ◽  
pp. 1780-1787 ◽  
Author(s):  
Alen Brkic ◽  
Lene Terslev ◽  
Uffe Møller Døhn ◽  
Søren Torp‐Pedersen ◽  
Wolfgang A. Schmidt ◽  
...  
2013 ◽  
Vol 213 (7) ◽  
pp. 338-346
Author(s):  
S. Pérez-Esteban ◽  
M.A. González-Gay ◽  
S. Castañeda

Medicine ◽  
2021 ◽  
Author(s):  
Muhamad Jasim ◽  
Caroline M. Cardy

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
F. David Carmona ◽  
◽  
Patrick Coit ◽  
Güher Saruhan-Direskeneli ◽  
José Hernández-Rodríguez ◽  
...  

Author(s):  
Konstanze Guggenberger ◽  
Thorsten Bley

Background Large vessel vasculitides comprise primary vasculitides of large and medium-sized arteries with various clinical, laboratory and radiological presentations. Imaging has become increasingly important in the diagnosis and monitoring of large vessel vasculitides. It complements clinical and laboratory examination and displays vasculitic changes of large extra- and intracranial arteries with relatively good diagnostic reliability and a low level of invasiveness. Method This review presents the most important imaging modalities and some typical imaging findings in the context of the two main forms of large vessel vasculitis, giant cell arteritis and Takayasu’s arteritis, with special regard to the recently launched EULAR (The European League Against Rheumatism) recommendations on the role of imaging in patients with suspected large vessel vasculitides. Results and Conclusion Color-coded duplex sonography (CCDS), magnetic resonance imaging (MRI), computed tomography (CT), and 18F-fluorodeoxyglucose positron emission tomography are today’s common imaging methods in large vessel vasculitides representing a reasonable and less invasive alternative or at least a good complement to temporal artery biopsy. Today’s EULAR guidelines recommend an imaging test as the first complementary method to clinical examination with CCDS as the preferred diagnostic test in suspected giant cell arteritis, MRI as the equivalent alternative in the case of inconclusive results, and MRI as the first choice in suspected Takayasu’s arteritis. Key Points:  Citation Format


2019 ◽  
Vol 28 (04) ◽  
pp. 215-225 ◽  
Author(s):  
Amer Harky ◽  
Matthew Fok ◽  
Callum Howard ◽  
Mohamad Bashir

AbstractLarge-vessel vasculitis encompasses the spectrum of vasculitides, which pathologically cause chronic granulomatous inflammatory changes, primarily in the aorta and its major branches. These patients are at risk of developing life-threatening aortic lesions that, without recognition and prompt treatment, can cause detrimental effects. Many provocative issues surrounding large-vessel vasculitis and its surgical treatment still remain, spanning from recognition to management. In this review, we discuss the main large-vessel vasculitides, Takayasu's arteritis and giant cell arteritis. We include the key points and current controversies surrounding diagnostic imaging, timing of interventions, and patient outcomes.


1998 ◽  
Vol 10 (1) ◽  
pp. 18-28 ◽  
Author(s):  
Maria C. Cid ◽  
Carme Font ◽  
Blanca Coll-Vinent ◽  
Josep M. Grau

Medicine ◽  
2006 ◽  
Vol 34 (11) ◽  
pp. 468-471 ◽  
Author(s):  
Caroline Gordon

2021 ◽  
Vol 23 (2) ◽  
Author(s):  
Joanna Robson ◽  
Sarah Mackie ◽  
Catherine Hill

Abstract Purpose of Review The goal of this paper is to review current and future uses of patient-reported outcomes in large vessel vasculitis. The large vessel vasculitides comprise Giant Cell Arteritis and Takayasu arteritis; both are types of systemic vasculitis which affect the larger blood vessels. Patient-reported outcomes (PROs) capture the impact of these diseases on health-related quality of life. Recent Findings Generic PROs such as the SF-36 are currently used to compare HRQOL of people with GCA and TAK within clinical trials and observational studies and to make comparisons with the general population and HRQoL in other diseases. The development of a disease-specific PRO for GCA is currently underway. Beyond clinical trials, there is much interest in the use of PROs within routine clinical care, particularly E-PROs for remote use. Summary Further work will be needed to complete the development of disease-specific PROs for people with large vessel vasculitis and to establish feasibility, acceptability, and utility of E-PROs.


Sign in / Sign up

Export Citation Format

Share Document